Skip to main content
Premium Trial:

Request an Annual Quote

Diatech, Janssen Partner to Develop Molecular Diagnostics for Bladder Cancer

NEW YORK – Diatech Pharmacogenetics on Tuesday said it has established a partnership with Janssen Pharmaceutica centered on improving access to precision medicine for patients with bladder cancer.

Diatech is developing an in vitro diagnostic assay to guide the use of precision medicine therapies for patients with bladder cancer based on their individual genetic profile. The goal of the project is to facilitate precision medicine testing worldwide by developing a highly sensitive test that can complete analysis of genetic alterations in the cancer in three hours using real-time PCR. 

The Jesi, Italy-based company announced in April that it expects an investment from private equity firm TA Associates in Q2 2023 to support its efforts to expand into international markets.

Diatech markets a line of PCR-based oncology kits including the easyPGX to detect KRAS, NRAS, BRAF, and EGFR with a turnaround time of less than three hours.


The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.